Awards

2009-2011 Landon Foundation-AACR INNOVATOR Award for International Collaboration in Cancer Research. Awarded to Principal Investigator: Josep M. Llovet, MD, on behalf of the HCC Genomic Consortium.

2010 Publications

Originals

  1. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman SL, Golub T, Mazzaferro V, Llovet JM. MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. Gastroenterology. 2011 Feb 12.

  2. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung SN, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Schwartz ME, Llovet JM.
    Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma.
    Gastroenterology. 2011 Feb 11.

  3. Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Solé M, Thung S, Moyano S, Toffanin S, Mínguez B, Cabellos L, Peix J, Schwartz M, Mazzaferro V, Bruix J, Llovet JM. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol. 2010 Apr;52(4):550-9.

Reviews

  1. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis. 2010 Feb;30(1):35-51. Epub 2010 Feb 19. Review.

  2. Toffanin S, Villanueva A, Llovet JM. miRNA delivery: emerging therapy for hepatocellular carcinoma. Gastroenterology. 2010 Mar;138(3):1202-4. Epub 2010 Jan 25.

  3. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med.2010;61:317-28. Review.

  4. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, SavicR, Cornella H, Llovet J. New Strategies in Hepatocellular Carcinoma:Genomic Prognostic Markers. Clin Cancer Res. 2010 Aug 16.

  5. Lachenmayer A, Hoshida Y, Llovet JM. Hippo tumor supressor pathway: novel implications for the treatment of hepatocellular carcinoma. Gastroenterology 2010;139:692-4.

  6. Lachenmayer A, Alsinet C, Chang CY, Llovet JM. Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S264-72.

  7. Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol. 2010;52:921-9.

2009 Publications

Originals

  1. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting Survival after Liver Transplantationin Patients with Hepatocellular Carcinoma beyond the Conventional Milan/UNOS Criteria. Lancet Oncology 2009;10:35-43

  2. Forner  A, Ayuso C, Varela M, Rimola J, Hessheimer A, Rodriguez C, Reig M, Bianchi L, Llovet JM, Bruix J. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. Cancer 2009;115:616-623.

  3. Yoo B, Emdad L, Su Z, Villanueva A, Chiang D, Mills AS, Waxman S,. Fisher R, Llovet JM, Fisher P, Sarkar D. Identification of a novel regulator of HCC. J Clin Invest 2009;1119:465-77.

  4. Keng V, Villanueva A, Chiang D,. Starr T, Silverstein K, Akagi K,  Tessarollo L, Matise I, Sarver A, Powers S,. Lowe S,. Collier L,. Dupuy A,Jenkins N,. Copeland N, Llovet JM, Largaespada D. A conditional transposon-based insertional mutagenesis system for modeling human cancer in mice. Nature Biotech 2009;27:264-74

  5. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-Fetoprotein, Des-gamma Carboxyprothrombin, and Lectin-Bound alpha-Fetoprotein in Early Hepatocellular Carcinoma. Gastroenterology 2009:137:110-118.

  6. Newell P, Toffanin S, Villanueva A, Chiang D, Minguez B, Cabellos L, Savic R, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K,  Fiel M, Thung S, Alsinet C, Tovar V, Hoshida Y, Bruix J, Roayaie S, Mazzaferro V,Schwartz M, Friedman S, Llovet JM. Ras Pathway Activation in Hepatocellular Carcinoma and anti-tumoral effect of double blockage with Sorafenib and Rapamycin in vivo. J Hepatol  2009;51:725-33.

  7. Viswanathan SR, Powers J, Einhorn W, Hoshida Y, Toffanin S, Mermel C, Lu J, Shah SP, Beroukhim R, Tanwar P, Azam M, Perez-Atayde A, Teixeira J, Meyerson M, Frazier L, Mullighan C, Radich J, Llovet JM, Golub TR, and Daley GQ. Lin28 enhances tumorigenesis and is associated with advanced human malignancies. Nature Genetics 2009;41:843-8

  8. Sasan Roayaie, Iris N. Blume, Swan N. Thung, Maria Guido*, Maria-Isabel Fiel, Spiros Hiotis, Daniel M. Labow, Josep M. Llovet, Myron Schwartz.. Novel Classification of Microscopic Vascular Invasion in Resected Hepatocellular Carcinoma. Gastroenterology 2009;137:950-5.

  9. Hoshida Y, Nijman S, Kobayashi M,. Chan J, Jean- Brunet P, Chiang D, Villanueva A, Newell P,Ikeda K, Hashimoto M, Watanabe G, Gabriel S,Friedman S, Kumada H, Llovet JM , Golub T. Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma. Cancer Research, 2009;69:7385-92

  10. Tovar V,  Alsinet C, Villanueva A, Chiang D,  Solé M,  Thung S, Moyano s, Toffanin S,  Mínguez B, Cabellos L,  Peix J, Schwartz M,  Mazzaferro V,  Bruix J,  Llovet JM.  IGF pathway deregulation in early HCC and pre-clinical efficacy of blocking IGF-1R. J Hepatol, 2009 (in press).

  11. Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, Llovet JM, Brenner DA, Schwabe RF. CCR1 and CCR5 promote hepatic fibrosis in mice J Clin Invest 2009: 119: 1858-70.

  12. Llovet JM, Peña C, Shan M, Lathia C, Bruix J. Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma (HCC) randomized in the phase III SHARP trial. Lancet Oncology  2009; (in preparation).

Editorials

  1. Llovet JM, Bruix J. Testing molecular therapies in HCC: the need of randomized phase II studies.  J Clin Oncol, 2009;27:833-5.

  2. Forner A, Llovet JM, Bruix JM Sunitinib and the benefits of a negative study. Lancet Oncol, 2009; 10:743-44.

Reviews

  1. Bruix J, Llovet JM. Hepatocellular carcinoma: from no hope to major achievements. Lancet 2009;373:614-16

  2. Hoshida Y, Villanueva A, Llovet JM. Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol. 2009 ;3:101-3.

  3. Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol. 2009;25:186-94.

  4. Villanueva A, Savic R, Llovet JM. Lymphotoxins: Novel targets for HCC. Cancer Cell 2009;16:272-273.